Keyphrases
Abstinence
6%
All-cause Mortality
16%
Associated Risk Factors
33%
Behavioral Model
6%
Benzodiazepines
39%
BUP-XR
100%
Buprenorphine
72%
Care Groups
7%
Clinical Endpoints
13%
Co-prescription
33%
Community-based
33%
Cost-effectiveness
66%
Drug-related Deaths
15%
Extended Release
66%
Extended-release Buprenorphine
100%
Health-related Quality of Life
13%
Intervention Evaluation
6%
Iterative Categorization
6%
Long-term Evaluation
6%
Maintenance Dose
9%
Medications for Opioid Use Disorder
13%
Methadone
75%
Mixed Methods Evaluation
37%
National Health Service
6%
Non-fatal Overdose
33%
Non-medical
6%
Opioid Replacement Therapy
39%
Opioid Use Disorder
71%
Opioids
25%
Oral Liquid
66%
Overdose Risk Factors
33%
Participant Recruitment
6%
Pharmacotherapy
33%
Phase II Trial
33%
Population-based Cohort Study
33%
Psychosocial Intervention
40%
Qualitative-quantitative
6%
Quality of Life Model
6%
Quality-adjusted Life Years
11%
Randomized Controlled Trial
70%
Related Topic
6%
Scotland
10%
Service Community
6%
Standard of Care
52%
Sublingual Buprenorphine
6%
Sublingual Tablets
66%
Substance Misuse Services
33%
Sussex
6%
Trial Registration
15%
Two-center
6%
Medicine and Dentistry
Abstinence
12%
Adverse Event
22%
Arm
8%
Base
5%
Buprenorphine
100%
Care Group
16%
Clinical Trial
15%
Combination Therapy
15%
Cost-Effectiveness Analysis
66%
Diagnosis
5%
Disease
8%
Drug Administration
5%
Drug Therapy
47%
DSM-5
5%
Group Therapy
17%
Health Care Cost
33%
Health Service
8%
Intention-to-Treat Analysis
11%
Maintenance Drug Dose
5%
Maintenance Therapy
11%
Methadone
72%
Methadone Treatment
5%
National Health Service
12%
Opiate
30%
Opiate Agonist
6%
Opioid Abuse
83%
Population Research
6%
Quality Adjusted Life Year
23%
Quality of Life
25%
Randomized Controlled Trial
66%
Social Interaction
6%
Substance Use
6%
